Evidence map›Paper›PMID 33476647›Full record

ArticleThe Journal of biological chemistry

A Legionella effector ADP-ribosyltransferase inactivates glutamate dehydrogenase.

Miles H Black, Adam Osinski, Gina J Park, Marcin Gradowski, Kelly A Servage, Krzysztof Pawłowski, Vincent S Tagliabracci

Open access · goldAbstract read
In one paragraph

Article in The Journal of biological chemistry. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
3.9field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. mLife · 2025
    Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Reversible modification of mitochondrial ADP/ATP translocases by pairedProceedings of the National Academy of Sciences of the United States of America · 2022
    Article
  10. Glycosylating Effectors ofBiomolecules · 2022
    Review
  11. eLife · 2022
    Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Miles H BlackDepartment of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Adam OsinskiDepartment of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Gina J ParkDepartment of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Marcin GradowskiInstitute of Biology, Warsaw University of Life Sciences, Warsaw, Poland.
Kelly A ServageDepartment of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, Texas, USA; Department of Molecular Biology, University of Texas Southwestern Medical Center, Howard Hughes Medical Institute, Dallas, Texas, USA.
Krzysztof PawłowskiDepartment of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, Texas, USA; Institute of Biology, Warsaw University of Life Sciences, Warsaw, Poland.
Vincent S TagliabracciDepartment of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, Texas, USA; Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA; Hamon Center for Regenerative Science and Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA. Electronic address: vincent.tagliabracci@utsouthwestern.edu.
The University of Texas Southwestern Medical Center · USWarsaw University of Life Sciences · PLHoward Hughes Medical Institute · USSouthwestern Medical Center · US

Funding

Breathing life into dead enzymesDP2GM137419 · NIGMS · UT SOUTHWESTERN MEDICAL CENTER · PI TAGLIABRACCI, VINCENT SCOTT · 2019 to 2020
$2.6M
Antioxidant signaling by protein AMPylationR01GM135189 · NIGMS · UT SOUTHWESTERN MEDICAL CENTER · PI TAGLIABRACCI, VINCENT SCOTT · 2020 to 2023
$1.3M
Lipoprotein Phosphorylation by Secretory Pathway KinasesF30HL143859 · NHLBI · UT SOUTHWESTERN MEDICAL CENTER · PI BLACK, MILES HENRY · 2018 to 2021
$102k
NHLBI NIH HHS F30 HL143859NIGMS NIH HHS DP2 GM137419NIGMS NIH HHS R01 GM135189
6 · The paper itself

Abstract

ADP-ribosyltransferases (ARTs) are a widespread superfamily of enzymes frequently employed in pathogenic strategies of bacteria. Legionella pneumophila, the causative agent of a severe form of pneumonia known as Legionnaire's disease, has acquired over 330 translocated effectors that showcase remarkable biochemical and structural diversity. However, the ART effectors that influence L. pneumophila have not been well defined. Here, we took a bioinformatic approach to search the Legionella effector repertoire for additional divergent members of the ART superfamily and identified an ART domain in Legionella pneumophila gene0181, which we hereafter refer to as Legionella ADP-Ribosyltransferase 1 (Lart1) (Legionella ART 1). We show that L. pneumophila Lart1 targets a specific class of 120-kDa NAD+-dependent glutamate dehydrogenase (GDH) enzymes found in fungi and protists, including many natural hosts of Legionella. Lart1 targets a conserved arginine residue in the NAD+-binding pocket of GDH, thereby blocking oxidative deamination of glutamate. Therefore, Lart1 could be the first example of a Legionella effector which directly targets a host metabolic enzyme during infection.

Indexed as

ADP Ribose TransferasesADP-RibosylationAmino Acid SequenceAmoebaAnimalsBacterial ProteinsBinding SitesCloning, MolecularDeaminationEscherichia coliFungiGene ExpressionGenetic VectorsGlutamate DehydrogenaseHost-Pathogen InteractionsKineticsADP Ribose TransferasesBacterial ProteinsGlutamate DehydrogenaseRecombinant ProteinsADP-ribosylationbacterial pathogenesisbioinformaticscell metabolismenzyme kineticsglutamateglutamate dehydrogenaseinfectious disease

Identifiers

PMID33476647
PMCPMC7949102
OpenAlexW3121192774

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.